829 related articles for article (PubMed ID: 18707731)
1. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
2. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
3. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
5. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
Reese AC; Cooperberg MR; Carroll PR
J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
7. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Ercole B; Marietti SR; Fine J; Albertsen PC
J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
9. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
10. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
11. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
12. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
15. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
17. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
Abouassaly R; Lane BR; Jones JS
Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
[TBL] [Abstract][Full Text] [Related]
18. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
Hegarty JM; Wallace M; Comber H
Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
[TBL] [Abstract][Full Text] [Related]
19. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Dall'era MA; Hosang N; Konety B; Cowan JE; Carroll PR
J Urol; 2009 Apr; 181(4):1622-7; discussion 1627. PubMed ID: 19230923
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
